|
1.
|
|
6 p, 754.7 KB |
Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer : a post hoc analysis of the MOSAIC trial
/
Auclin, Edouard (Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France) ;
André, Thierry (Oncology Multidisciplinary Research Group (GERCOR)) ;
Taieb, Julien (UMR-S 1147, INSERM) ;
Banzi, Maria (Unit of Medical Oncology, Clinical Cancer Center, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy) ;
Van Laethem, Jean-Luc (Université Libre de Bruxelles. Department of Gastroenterology and Digestive diseases, Hopital Erasme) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Hickish, Tamas (Royal Bournemouth Hospital and Bournemouth University. Department of Oncology) ;
de Gramont, Aimery (Institut Hospitalier Franco-Britannique. Department of Oncology) ;
Vernerey, Dewi (Oncology Multidisciplinary Research Group (GERCOR)) ;
Universitat Autònoma de Barcelona
Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2. 35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial assessed post-operative CEA prognostic value for survival outcomes and predictive value for the addition of oxaliplatin to adjuvant treatment. [...]
2019 -  10.1038/s41416-019-0521-7
British Journal of Cancer, Vol. 121 (july 2019) , p. 312-317
|
|
|
2.
|
|
14 p, 2.2 MB |
Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer
/
Aguado, Cristina (Quirón Dexeus University Hospital) ;
Teixido, Cristina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Román, Ruth (Quirón Dexeus University Hospital) ;
Reyes, Roxana (Hospital Clínic i Provincial de Barcelona) ;
Giménez-Capitán, Ana (Quirón Dexeus University Hospital) ;
Marin, Elba (Hospital Clínic i Provincial de Barcelona) ;
Cabrera, Carlos (Dexeus University Hospital Quiron Salud Group) ;
Viñolas, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Castillo, Sergi (Hospital General de Granollers) ;
Muñoz, Silvia (Hospital General de Granollers) ;
Arcocha, Ainara (Hospital Clínic i Provincial de Barcelona) ;
López-Vilaró, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Aldeguer, Erika (Quirón Dexeus University Hospital) ;
Rodríguez, Sonia (Quirón Dexeus University Hospital) ;
Moya, Irene (Dexeus University Hospital Quiron Salud Group) ;
Viteri, Santiago (Quiron Salud Group) ;
Cardona, Andrés Felipe (Clínica del Country) ;
Palmero, Ramon (L'Hospitalet) ;
Sainz, Cristina (CIBERONC) ;
Mesa-Guzmán, Miguel (Universidad Pública de Navarra) ;
Lozano, Maria D. (Universidad Pública de Navarra) ;
Aguilar-Hernández, Andrés (Dexeus University Hospital Quiron Salud Group) ;
Martínez-Bueno, Alejandro (Dexeus University Hospital Quiron Salud Group) ;
González-Cao, María (Dexeus University Hospital Quiron Salud Group) ;
Gonzalvo, Elena (Hospital Clínic i Provincial de Barcelona) ;
Leenders, William P. J. (Radboud Institute for Molecular Life Sciences) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Montuenga, Luis M. (Universidad Pública de Navarra) ;
Prat, Aleix (Hospital Clínic i Provincial de Barcelona) ;
Molina-Vila, Miguel Angel (Quirón Dexeus University Hospital) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona)
We studied MET alterations in 474 advanced non-small-cell lung cancer (NSCLC) patients by nCounter, an RNA-based technique. We identified 3% with MET Δex14 mRNA and 3. 5% with very-high MET mRNA expression, a surrogate of MET amplification. [...]
2020 - 10.1002/1878-0261.12861
Molecular Oncology, Vol. 15 (december 2020) , p. 350-363
|
|
|
3.
|
|
14 p, 1.3 MB |
Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools
/
Besso, María josé (Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET)-Fundación IBYME (FIBYME)) ;
Montivero, Luciana (Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET)-Fundación IBYME (FIBYME)) ;
Lacunza, Ezequiel (Centro de Investigaciones Inmunológicas, Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata) ;
Argibay, María cecilia (Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET)-Fundación IBYME (FIBYME)) ;
Abba, Martín (Centro de Investigaciones Inmunológicas, Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata) ;
Furlong, Laura Inés (Integrative Biomedical Informatics Group, Research Programme on Biomedical Informatics, Hospital del Mar Medical Research Institute, Department of Experimental and Health Sciences, Universitat Pompeu Fabra) ;
Colas, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gil-Moreno, Antonio (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Reventos, Jaume (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bello, Ricardo (Departamento de Metodología, Estadística y Matemática, Universidad de Tres de Febrero) ;
Vazquez-Levin, Mónica Hebe (Laboratorio de Estudios de Interacción Celular en Reproducción y Cáncer, Instituto de Biología y Medicina Experimental (IBYME), Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET)-Fundación IBYME (FIBYME)) ;
Universitat Autònoma de Barcelona
Endometrial cancer (EC) is the sixth most common cancer in women worldwide. Early diagnosis is critical in recurrent EC management. The present study aimed to identify biomarkers of EC early recurrence using a workflow that combined text and data mining databases (DisGeNET, Gene Expression Omnibus), a prioritization algorithm to select a set of putative candidates (ToppGene), protein-protein interaction network analyses (Search Tool for the Retrieval of Interacting Genes, cytoHubba), association analysis of selected genes with clinicopathological parameters, and survival analysis (Kaplan-Meier and Cox proportional hazard ratio analyses) using a The Cancer Genome Atlas cohort. [...]
2020 - 10.3892/or.2020.7648
Oncology Reports, Vol. 44 (june 2020) , p. 873-886
|
|
|
4.
|
|
12 p, 2.0 MB |
The extent of aortic lymphadenectomy in locally advanced cervical cancer impacts on survival
/
Llueca, Antoni (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellón, Department of Medicine, Universitat Jaume I (UJI)) ;
Escrig, Javier (Multidisciplinary Unit of Abdominal Pelvic Oncology Surgery (MUAPOS), University General Hospital of Castellón, Department of Medicine, Universitat Jaume I (UJI)) ;
Gil-Moreno, Antonio (Hospital Universitari Vall d'Hebron) ;
Benito, Virginia (Department of Gynecologic Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil) ;
Hernández, Alicia (Department of Gynecology, Hospital Universitario La Paz) ;
Díaz-Feijoo, Berta (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Universitat Autònoma de Barcelona
The prognostic impact of surgical paraaortic staging remains unclear in patients with locally advanced cervical cancer (LACC). The objective of our study was to evaluate the results of the surgical technique of preoperative aortic lymphadenectomy in LACC related to tumor burden and disease spread to assess its influence on survival. [...]
2020 - 10.3802/jgo.2021.32.e4
Journal of Gynecologic Oncology, Vol. 32 (october 2020)
|
|
|
5.
|
|
13 p, 2.0 MB |
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
/
Garrido-Castro, Ana C. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ;
Saura, Cristina (SOLTI Breast Cancer Research Group, Barcelona) ;
Barroso-Sousa, Romualdo (Present Address: Hospital Sírio-Libanês, Brasilia, Brazil) ;
Guo, Hao (Dana-Farber Cancer Institute. Division of Biostatistics, Department of Data Sciences) ;
Ciruelos, Eva (Hospital 12 de Octubre (Madrid)) ;
Bermejo, Begoña (CIBERONC-ISCIII. Clinic University Hospital, INCLIVA Biomedical Research Institute) ;
Gavilá, Joaquin (Fundación Instituto Valenciano De Oncología) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia) ;
Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paré, Laia (SOLTI Breast Cancer Research Group) ;
Céliz, Pamela (SOLTI Breast Cancer Research Group) ;
Villagrasa, Patricia (SOLTI Breast Cancer Research Group) ;
Li, Yisheng (The University of Texas MD Anderson Cancer Center. Department of Biostatistics, Division of Basic Sciences) ;
Savoie, Jennifer (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ;
Xu, Zhan (Northern Arizona University. School of Communication) ;
Arteaga, Carlos L. (UT Southwestern Medical Center. Harold C. Simmons Comprehensive Cancer Center) ;
Krop, Ian E. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ;
Solit, David B. (Memorial Sloan Kettering Cancer Center. Kravis Center for Molecular Oncology) ;
Mills, Gordon B. (The University of Texas MD Anderson Cancer Center. Present Address: Division of Basic Science Research, Department of Systems Biology) ;
Cantley, Lewis C. (Sandra and Edward Meyer Cancer Center, Weill Cornell Medical College) ;
Winer, Eric P. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ;
Lin, Nancy U. (Harvard Medical School. Department of Medical Oncology, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute) ;
Rodon, Jordi (The University of Texas MD Anderson Cancer Center. Present Address: Department of Investigational Cancer Therapeutics) ;
Universitat Autònoma de Barcelona
Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss of PTEN and/or INPP4B is common. Buparlisib is an orally bioavailable, pan-class I PI3K inhibitor. [...]
2020 - 10.1186/s13058-020-01354-y
Breast cancer research, Vol. 22 (november 2020)
|
|
|
6.
|
|
|
7.
|
|
20 p, 1.6 MB |
Community risk factors in the COVID-19 incidence and mortality in Catalonia (Spain) : a population-based study
/
Zaldo-Aubanell, Quim (Universitat Autònoma de Barcelona. Institut de Ciència i Tecnologia Ambientals) ;
Olivet-Vila, Joan (Agència de Salut Pública de Catalunya. Servei de Promoció de la Salut a Girona) ;
Saez, Marc (Universitat de Girona. Grup de Recerca en Estadística, Econometria i Salut) ;
Pino, David (Universitat Politècnica de Catalunya. Departament de Física) ;
Maneja Zaragoza, Roser (Universitat Autònoma de Barcelona. Departament de Geografia) ;
Campillo i López,Ferran (Centre de Ciència i Tecnologia Forestal de Catalunya. Laboratori de Medi Ambient i Salut Humana) ;
Bach Pagès, Albert (Centre de Ciència i Tecnologia Forestal de Catalunya. Laboratori de Medi Ambient i Salut Humana) ;
Serra, Isabel (Centre de Recerca Matemàtica)
The heterogenous distribution of both COVID-19 incidence and mortality in Catalonia (Spain) during the firsts moths of the pandemic suggests that differences in baseline risk factors across regions might play a relevant role in modulating the outcome of the pandemic. [...]
2021 - 10.3390/ijerph18073768
International journal of environmental research and public health, Vol. 18, Issue 7 (April 2021) , art. 3768
|
|
|
8.
|
|
12 p, 700.5 KB |
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain : OSIREX-Spanish Lung Cancer Group
/
Provencio, Mariano (Universidad Autónoma de Madrid) ;
Terrasa, Josefa (Hospital Universitari Son Espases. Medical Oncology Department) ;
Garrido, Pilar (IRYCIS Hospital Universitario Ramón y Cajal. Medical Oncology Department) ;
Campelo, Rosario García (Instituto de Investigación Biomédica A Coruña INIBIC) ;
Aparisi, Francisco (Hospital General Universitario de Valencia. Medical Oncology Department Valencia) ;
Diz, Pilar (Complejo Asistencial Universitario de León. Medical Oncology Department León) ;
Aguiar, David (Hospital Universitario de Gran Canaria Dr. Negrín. Medical Oncology Department) ;
García-Giron, Carlos (Hospital Universitario De Burgos. Medical Oncology Department) ;
Hidalgo, Julia (Hospital Lluís Alcanyis. Medical Oncology Department) ;
Aguado, Carlos (Hospital Clínico San Carlos (Madrid)) ;
González, Jorge García (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Esteban, Emilio (Hospital Universitario Central de Asturias. Medical Oncology Department) ;
Gómez-Aldavarí, Lorenzo (Complejo Hospitalario Universitario de Albacete) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Juan, Oscar (Hospital Universitari i Politècnic La Fe. Medical Oncology Department) ;
Chara, Luís Enrique (Hospital Universitario de Guadalajara. Medical Oncology Department) ;
Marti, Juan L. (Hospital General Universitario de Alicante. Medical Oncology Department) ;
Castro, Rafael López (Hospital Clínico Universitario (Valladolid)) ;
Ortega, Ana Laura (Complejo Hospitalario de Jaen. Medical Oncology Department) ;
Moreno, Elia Martínez (Hospital Virgen de la Salud. Medical Oncology Department) ;
Coves, Juan (Hospital Son Llàtzer. Medical Oncology Department) ;
Sánchez Peña, Ana M. (Hospital Universitario de Getafe. Medical Oncology Department) ;
Bosch-Barrera, Joaquim (Hospital Universitari de Girona Doctor Josep Trueta) ;
Gastaldo, Amparo Sánchez (Hospital Universitario Virgen del Rocío. Medical Oncology Department) ;
Núñez, Natalia Fernández (Hospital Universitario Lucus Augusti. Medical Oncology Department) ;
del Barco, Edel (Hospital Universitario de Salamanca. Medical Oncology Department) ;
Cobo, Manuel (Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Unidad de Gestión Clínica Intercentros de Oncología Médica) ;
Isla, Dolores (Hospital Universitario Lozano Blesa. Medical Oncology Department) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Navarro, Fátima (Hospital Universitario Príncipe de Asturias. Medical Oncology Department) ;
Calvo, Virginia (Health Research Institute, Hospital Universitario Puerta de Hierro) ;
Universitat Autònoma de Barcelona
AURA study reported 61% objective response rate and progression-free survival of 9. 6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to describe the experience with osimertinib in Spain. [...]
2021 - 10.1186/s12885-021-07922-5
BMC Cancer, Vol. 21 (march 2021)
|
|
|
9.
|
|
|
10.
|
|
9 p, 2.0 MB |
Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel
/
Pasculli, B. (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia) ;
Barbano, R. (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia) ;
Rendina, M. (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia) ;
Fontana, A. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Biostatistica) ;
Copetti, M. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Biostatistica) ;
Mazza, T. (Fondazione IRCCS Casa Sollievo della Sofferenza. Bioinformatics Unit) ;
Valori, V.M. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Oncologia) ;
Morritti, M. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Oncologia) ;
Maiello, E. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Oncologia) ;
Graziano, P. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Anatomia Patologica) ;
Murgo, R. (Fondazione IRCCS Casa Sollievo della Sofferenza. UO di Chirurgia Senologica) ;
Fazio, V.M. (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Parrella, P. (Fondazione IRCCS Casa Sollievo della Sofferenza Laboratorio di Oncologia) ;
Universitat Autònoma de Barcelona
MicroRNA-210-3p is the most prominent hypoxia regulated microRNA, and it has been found significantly overexpressed in different human cancers. We performed the expression analysis of miR-210-3p in a retrospective cohort of breast cancer patients with a median follow-up of 76 months (n = 283). [...]
2019 - 10.1038/s41598-019-51581-3
Scientific reports (Nature Publishing Group), Vol. 9 Núm. 1 (january 2019) , p. 14913
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
